LEK-8842
LEK-8842, also known as N-methyl-N-(2-propynyl)lysergamide or as TRALA-01, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD.
≈ 2 min read
LEK-8842. encyclopegia.org, snapshot enwiki-001364275221. /a/lek-8842
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
LEK-8842, also known as N-methyl-N-(2-propynyl)lysergamide or as TRALA-01, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD. The drug is described as showing serotonin 5-HT 2 receptor partial agonistic activity and α-adrenergic receptor agonistic activity based on in-vitro tissue assays that included selective antagonist challenges.
Subsequently, it was found to be a potent partial agonist of the serotonin 5-HT 2A and 5-HT 2B receptors and to show affinity for the serotonin 5-HT 2C receptor. LEK-8842 produces effects in animals including serotonin behavioral syndrome, hyperthermia, pressor effects, pupil dilation, and uterine contractions. The chemical synthesis of LEK-8842 has been described.
Several analogues of LEK-8842 have been described, for instance LEK-8804 (N-(2-propynyl)lysergamide) among others. LEK-8842 was first described in the scientific literature by 1992. It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.
Subsequently, LEK-8842 was studied and patented by Matthias Liechti and Daniel Trachsel and colleagues in association with Mind Medicine (Definium Therapeutics) in 2023.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1364275221 under CC BY-SA 4.0; modifications have been made.